Cargando…

Correction to: Migalastat: A Review in Fabry Disease

Detalles Bibliográficos
Autores principales:	McCafferty, Emma H., Scott, Lesley J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684498/ https://www.ncbi.nlm.nih.gov/pubmed/31292908 http://dx.doi.org/10.1007/s40265-019-01166-1

Ejemplares similares

Migalastat: A Review in Fabry Disease
por: McCafferty, Emma H., et al.
Publicado: (2019)

Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
por: Lenders, Malte, et al.
Publicado: (2020)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
por: Benjamin, Elfrida R., et al.
Publicado: (2017)

Correction: Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Publicado: (2018)

Pregnancy Outcome after Exposure to Migalastat for Fabry Disease: A Clinical Report
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2019)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease
por: Schiffmann, Raphael, et al.
Publicado: (2019)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists
por: Jaurretche, Sebastián, et al.
Publicado: (2022)

Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
por: Bichet, Daniel G., et al.
Publicado: (2023)

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
por: Pogoda, Christian, et al.
Publicado: (2023)

Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
por: Müntze, Jonas, et al.
Publicado: (2019)

Correction: Global computational mutagenesis provides a critical stability framework in protein structures
por: McCafferty, Caitlyn L., et al.
Publicado: (2018)

Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report
por: Di Stefano, Valeria, et al.
Publicado: (2021)

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
por: Schiffmann, Raphael, et al.
Publicado: (2018)

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
por: Riccio, Eleonora, et al.
Publicado: (2020)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease
por: Gatterer, Constantin, et al.
Publicado: (2023)

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
por: Müntze, Jonas, et al.
Publicado: (2019)

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
por: Hughes, Derralynn A., et al.
Publicado: (2019)

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
por: Perretta, Fernando, et al.
Publicado: (2023)

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
por: Germain, Dominique P., et al.
Publicado: (2019)

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease
por: Rob, Daniel, et al.
Publicado: (2017)

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
por: Hughes, Derralynn A, et al.
Publicado: (2017)

Correction: Fabry disease due to D313Y and novel GLA mutations
Publicado: (2018)

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase
por: Warnock, David G., et al.
Publicado: (2015)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Correction to: Ultrasonic signal detection based on Fabry–Perot cavity sensor
por: Yang, Wu, et al.
Publicado: (2021)

Correction to: Eravacycline: A Review in Complicated Intra-Abdominal Infections
por: Scott, Lesley J.
Publicado: (2019)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Correction: Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience
por: Effraimidis, Grigoris, et al.
Publicado: (2023)

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2022)

The gut microbiome and the ketogenic diet: A pathway towards treatment optimization in infantile spasms
por: McCafferty, Cian
Publicado: (2022)

Goldmann and error correcting tonometry prisms compared to intracameral pressure
por: McCafferty, Sean, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4e98nmdqnfuun3751dq2rnrkit